Suboxone: History, controversy, and open questions
There are more than 200 opioid overdose deaths each day in the US. In combating this epidemic we look to available treatment tools. Here, we find only three medications approved by the Food and Drug Administration (FDA) for the treatment of opioid use disorder. Of the three, buprenorphine is of part...
Main Authors: | Andy Sivils, Paige Lyell, John Q. Wang, Xiang-Ping Chu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1046648/full |
Similar Items
-
A qualitative examination of the current management of opioid use disorder and barriers to prescribing buprenorphine in a Canadian emergency department
by: David Wiercigroch, et al.
Published: (2021-04-01) -
Assessing suboxone access in community pharmacies: Secret shopper model
by: Bethany A. DiPaula, et al.
Published: (2023-12-01) -
Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021
by: Brandon del Pozo, et al.
Published: (2023-03-01) -
Implementation of a regional quality improvement collaborative to improve care of people living with opioid use disorder in a Canadian setting
by: Laura Beamish, et al.
Published: (2019-09-01) -
Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial
by: James S. H. Wong, et al.
Published: (2021-02-01)